{"product_id":"global-pneumonia-therapeutics-market-size-study-forecast-by-therapeutics-prevention-vaccines-and-treatment-drugs-by-distribution-channel-hospitals-pharmaceutical-stores-and-others-and-by-age-group-pediatric-adult-and-geriatric-and-regional","title":"Global Pneumonia Therapeutics Market Size study \u0026 Forecast, by Therapeutics (Prevention Vaccines and Treatment Drugs), by Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), and by Age Group (Pediatric, Adult, and Geriatric) and Regional","description":"\u003cp\u003eGlobal Pneumonia Therapeutics Market Size study \u0026amp; Forecast, by Therapeutics (Prevention Vaccines and Treatment Drugs), by Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), and by Age Group (Pediatric, Adult, and Geriatric) and Regional Analysis, 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eGlobal Pneumonia Therapeutics Market is valued approximately USD 13.24 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period 2022-2029. Pneumonia is a type of acute respiratory infection that inflames the air sacs in one or both lungs caused by bacteria, viruses, or fungi. The signs and symptoms of Pneumonia include cough, with greenish, yellow, and bloody mucus, fever, sweating, shortness of breath, rapid, shallow breathing, and stabbing chest pain among others. The increasing incidences of pneumonia and growing unmet clinical needs as well as strategic initiatives from leading market players are key factors accelerating the market growth.\u003c\/p\u003e\n\n\u003cp\u003eAccording to UNICEF – as of 2019, globally around 700,000 children under five lost their lives every year, accounting for around 2,000 deaths every day. In addition, South Asia (2,500 cases per 100,000 children) is the most affected region followed by West and Central Africa (1,620 cases per 100,000 children). Also, rising healthcare spending in developing regions and growing number of R\u0026amp;D activities in pharmaceuticals sector would create lucrative growth prospectus for the market over the forecast period. However, a high treatment cost and lack of awareness towards preventive vaccines impede the market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Pneumonia Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of revenue due to presence of leading pharmaceutical giants as well as availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric population and increasing prevalence of pneumonia in children in the region.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nBayer AG\u003cbr\u003e\nEli Lilly \u0026amp; Company\u003cbr\u003e\n GlaxoSmithKline PLC.\u003cbr\u003e\n Lupin Pharmaceuticals, Inc.\u003cbr\u003e\n Merck KGAA\u003cbr\u003e\n Novartis AG\u003cbr\u003e\n Pfizer, Inc.\u003cbr\u003e\n Sanofi S.A.\u003cbr\u003e\nTeva Pharmaceuticals Industries Limited.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\nIn December 2020, India based Serum Institute of India launched first indigenous vaccine for pneumonia. The new vaccines would be provided for children throughout the world with the help of UNICEF network.\u003c\/p\u003e\n\n\u003cp\u003eIn July 2021, US based Merck received the U.S. Food and Drug Administration (FDA) approval for its new VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) intended for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.\u003c\/p\u003e\n\n\n\u003cp\u003eGlobal Pneumonia Therapeutics Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered\u003c\/p\u003e\n\n \u003cp\u003eTherapeutics, Distribution Channel, Age Group, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003cbr\u003e\nCustomization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional \u0026amp; segment scope*\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:\u003cbr\u003e\nBy Therapeutics\u003cbr\u003e\nPrevention Vaccines\u003cbr\u003e\nTreatment Drugs\u003cbr\u003e\nBy Distribution Channel\u003cbr\u003e\nHospitals\u003cbr\u003e\n Pharmaceutical Stores\u003cbr\u003e\nOther\u003cbr\u003e\nBy Age Group\u003cbr\u003e\nPediatric\u003cbr\u003e\n Adult\u003cbr\u003e\nGeriatric\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRest of the WorldCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories \u003cbr\u003e\nBayer AG\u003cbr\u003e\nEli Lilly \u0026amp; Company\u003cbr\u003e\nGlaxoSmithKline PLC.\u003cbr\u003e\nLupin Pharmaceuticals, Inc.\u003cbr\u003e\nMerck KGAA\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nPfizer, Inc.\u003cbr\u003e\nSanofi S.A.\u003cbr\u003e\nTeva Pharmaceuticals Industries Limited.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 200 Pages \/ MCW16233694","offer_id":47650817474866,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-pneumonia-therapeutics-market-size-study-forecast-by-therapeutics-prevention-vaccines-and-treatment-drugs-by-distribution-channel-hospitals-pharmaceutical-stores-and-others-and-by-age-group-pediatric-adult-and-geriatric-and-regional","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}